Royal Bank Of Canada Albireo Pharma, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.01 - $23.78 $34,507 - $45,562	1,916 Added 398.34%	2,397 $51,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $5,728 - $9,255	351 Added 270.0%	481 $10,000
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $16,797 - $33,784	-906 Reduced 87.45%	130 $3,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $64,973 - $91,570	-2,714 Reduced 72.37%	1,036 $31,000
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $48,842 - $72,123	2,305 Added 159.52%	3,750 $87,000

Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $5,198 - $6,836	190 Added 15.14%	1,445 $45,000
Q2 2021 Aug 16, 2021	BUY	$28.9 - $36.87 $36,269 - $46,271	1,255 New	1,255 $45,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.